NEJM data and RMAT in hand, PM359 races toward a BLA on single-patient proof-of-concept while cash runs to 2027

Bull

A successful H1 2027 BLA submission — built on the published NEJM Phase 1/2 data showing durable NADPH oxidase restoration and clean safety in a single-patient proof-of-concept — triggers FDA's accelerated approval pathway enabled by RMAT, Fast Track, and Rare Pediatric Disease designations. Acceptance and priority review would de-risk the path to first approval, establish proof of platform, and likely attract partnership or financing interest well ahead of a PDUFA date.

Bear

The most likely failure mode is FDA declining to accept a BLA based on single-patient data as sufficient evidence for accelerated approval, requiring additional patients or longer follow-up before submission can proceed — directly extending the timeline and pressuring the cash runway that already runs only to 2027. A second risk is that CMC, manufacturing scalability, or comparability data required for a BLA cannot be completed within the projected window given the program's prior strategic deprioritization.